EU Orphan Drug Designation – overcoming regulatory challenges

Since the introduction of the EU orphan legislation in 2000, treatments for rare diseases now account for approximately 25% of all marketing authorization applications in the EU (EMA annual report, 2020). Clearly, the incentives offered by the ODD process have encouraged sponsors to pursue innovations in this domain. Yet while orphan status has been granted to more than 2,300 medicines, only 192 have received marketing authorization. There is no question that success or failure depends on multiple factors. But sponsors can amplify their prospects for gaining authorization by better understanding the regulatory considerations involved in bringing their innovations to patients awaiting them.

Open PDF

Return to Insights Center

Related Insights


Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


EU-CTR: Preparing for trial transition

Nov 30, 2023


Parexel names first Patient Ambassador

Jun 17, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022


Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021